1.60
price up icon2.56%   0.04
after-market Handel nachbörslich: 1.60
loading
Schlusskurs vom Vortag:
$1.56
Offen:
$1.53
24-Stunden-Volumen:
63,867
Relative Volume:
0.90
Marktkapitalisierung:
$90.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-2.1425
EPS:
-0.7468
Netto-Cashflow:
$-41.02M
1W Leistung:
+2.24%
1M Leistung:
+2.56%
6M Leistung:
+15.94%
1J Leistung:
+15.94%
1-Tages-Spanne:
Value
$1.52
$1.60
1-Wochen-Bereich:
Value
$1.49
$1.60
52-Wochen-Spanne:
Value
$1.14
$2.10

Inflarx N V Stock (IFRX) Company Profile

Name
Firmenname
Inflarx N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
66
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-08
Name
Neueste SEC-Einreichungen
Name
IFRX's Discussions on Twitter

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-04-05 Hochstufung Guggenheim Neutral → Buy
2022-02-28 Herabstufung Guggenheim Buy → Neutral
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-03-11 Hochstufung Guggenheim Neutral → Buy
2020-11-06 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-10-08 Eingeleitet H.C. Wainwright Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-04-30 Hochstufung Raymond James Mkt Perform → Outperform
2019-06-05 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-06-05 Herabstufung Guggenheim Buy → Neutral
2019-06-05 Herabstufung JP Morgan Overweight → Underweight
2019-06-05 Herabstufung Robert W. Baird Outperform → Neutral
2019-06-05 Herabstufung SunTrust Buy → Hold
2019-01-29 Eingeleitet Robert W. Baird Outperform
2018-12-10 Eingeleitet Credit Suisse Outperform
2018-07-13 Eingeleitet BMO Capital Markets Outperform
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-28 Eingeleitet SunTrust Buy
2018-02-08 Eingeleitet B. Riley FBR, Inc. Buy
Alle ansehen

Inflarx N V Aktie (IFRX) Neueste Nachrichten

pulisher
Nov 01, 2024

InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire

Oct 31, 2024
pulisher
Oct 14, 2024

InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat

Oct 14, 2024
pulisher
Sep 26, 2024

InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com

Sep 26, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress By Investing.com - Investing.com Australia

Sep 25, 2024
pulisher
Sep 05, 2024

InflaRx Announces Participation in September Investor Events - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx presents new preclinical findings for INF904 - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire

Sep 03, 2024
pulisher
Sep 01, 2024

InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat

Sep 01, 2024
pulisher
Aug 13, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat

Aug 13, 2024
pulisher
Aug 08, 2024

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx N.V. Reports Mid-Year Financial Results - TipRanks

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks

Aug 08, 2024
pulisher
Aug 07, 2024

InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World

Aug 07, 2024
pulisher
Aug 02, 2024

InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat

Aug 02, 2024
pulisher
Aug 01, 2024

InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewswire

Aug 01, 2024
pulisher
Jul 30, 2024

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewswire

Jul 30, 2024
pulisher
Jul 15, 2024

Vasculitis Treatment Market with Tremendous growth by 2031 – Glaxosmithkline plc, Amneal Pharmaceuticals, Inc., ChemoCentryx, InflaRx N.V – TIMC - TIMC

Jul 15, 2024
pulisher
Jul 14, 2024

InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June - American Banking and Market News

Jul 14, 2024
pulisher
Jul 12, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Expands By 151.1% - MarketBeat

Jul 12, 2024
pulisher
Jul 12, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 151.1% - Defense World

Jul 12, 2024
pulisher
Jun 28, 2024

InflaRx Announces $75M Share Sales Agreement - TipRanks

Jun 28, 2024
pulisher
Jun 28, 2024

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia

Jun 28, 2024
pulisher
Jun 28, 2024

InflaRx (NASDAQ:IFRX) Short Interest Update - MarketBeat

Jun 28, 2024
pulisher
Jun 27, 2024

What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)? - Yahoo New Zealand News

Jun 27, 2024
pulisher
Jun 26, 2024

SEC Form 424B5 filed by InflaRx N.V. - Quantisnow

Jun 26, 2024
pulisher
Jun 25, 2024

InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 25, 2024
pulisher
Jun 24, 2024

InflaRx's ARDS drug selected for BARDA Phase 2 study - Investing.com India

Jun 24, 2024
pulisher
Jun 24, 2024

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Jun 24, 2024
pulisher
Jun 24, 2024

Iron Mountain executive sells over $547k in company stock By Investing.com - Investing.com UK

Jun 24, 2024
pulisher
Jun 24, 2024

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - WICZ

Jun 24, 2024
pulisher
Jun 24, 2024

InflaRx's GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire

Jun 24, 2024
pulisher
Jun 24, 2024

InflaRx’s GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire

Jun 24, 2024
pulisher
Jun 07, 2024

InflaRx's (IFRX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jun 07, 2024
pulisher
Jun 06, 2024

InflaRx's (IFRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Jun 06, 2024
pulisher
Jun 05, 2024

InflaRx Hosts R&D Event Highlighting the Promise of INF904 - GlobeNewswire

Jun 05, 2024
pulisher
Jun 03, 2024

InflaRx (NASDAQ:IFRX) Trading Up 10.5% - MarketBeat

Jun 03, 2024

Finanzdaten der Inflarx N V-Aktie (IFRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):